sucralfate (redirected from Nu-Sucralfate)

sucralfate /su·cral·fate/ (soo-kral´fāt) a complex of aluminum and a sulfated polysaccharide, used as a gastrointestinal antiulcerative.

---

su·cral·fate (s-krlft)

n.

A polysaccharide with antipeptic activity used to treat duodenal ulcers.

---

sucralfate [soo-kral´fāt]

a complex of aluminum and a sulfated polysaccharide, used as a gastrointestinal antiulcerative and gastric mucosa protectant; administered orally.

---

sucralfate (sookral´fāt),

n brand name: Carafate;
drug class: protectant, aluminum salt of sulfated sucrose;
action: forms an ulcer-adherent complex that covers and protects the ulcer site;
use: treatment of duodenal ulcer.

---

sucralfate

a complex of aluminum hydroxide and sulfated sucrose used for short-term treatment of peptic ulcer; it forms a complex with proteins that resists digestion by acid and pepsin thereby making a protective coating for the ulcer.

---

sucralfate

Antepsin (UK), Carafate, Nu-Sucralfate (CA), PMS-Sucralfate (CA), Sulcrate (CA)

Pharmacologic class: GI protectant

Therapeutic class: Antiulcer agent

Pregnancy risk category B

Action

Combines with gastric acid to form protective coating on ulcer surface, inhibiting gastric acid secretion, pepsin, and bile salts

Availability

Oral suspension: 500 mg/5 ml

Tablets: 1 g

⊘Indications and dosages

➣ Active duodenal ulcer

Adults: 1 g P.O. q.i.d. 1 hour before meals and at bedtime or 2 g b.i.d. for 4 to 8 weeks. For maintenance, 1 g P.O. b.i.d.

Off-label uses

• Gastroesophageal reflux
• GI symptoms caused by nonsteroidal anti-inflammatory drugs (including aspirin)
• Prevention of stress ulcers and GI bleeding in critically ill patients
• Oral and esophageal ulcers caused by radiation, chemotherapy, or sclerotherapy (oral suspension)

Contraindications

None

Precautions

Use cautiously in:
• renal failure
• pregnant or breastfeeding patients
• children.

Administration

• When giving through nasogastric tube, reconstitute drug and flush tube with water after administration.

Route	Onset	Peak	Duration
P.O.	Unknown	Unknown	6 hr

Adverse reactions

EENT: rhinitis

GI: constipation

Respiratory: respiratory difficulty

Skin: pruritus, rash

Other: facial swelling, hypersensitivity reaction

Interactions

Drug-drug. Aluminum-containing antacids: increased total body burden of aluminum

Anticoagulants: decreased hypoprothrombinemic effect

Diclofenac: decreased pharmacologic effects of diclofenac

Digoxin, quinidine: reduced blood levels and efficacy of these drugs

Histamine₂-receptor antagonists (such as cimetidine, ranitidine), fluoroquinolones, ketoconazole, tetracyclines, theophylline: decreased bioavailability of these drugs

Levothyroxine, penicillamine: decreased efficacy of these drugs

Phenytoin: decreased phenytoin absorption

Patient monitoring

• Monitor bowel pattern. Report severe, ongoing constipation.
• Assess for rash and itching.

Patient teaching

• Tell patient to take 1 hour before meals and again at bedtime.
• Caution patient not to take within 30 minutes of antacids or other drugs.
• Explain importance of completing entire course of therapy as prescribed, even after pain and other ulcer symptoms improve.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

---

sucralfate

A complex of sucrose sulfate and AlOH, used to prevent acute gastric injury, ↓ inflammation, heal peptic ulcers Side effects Constipation, dry mouth, N&V, headache, urticaria, rashes